If you do joint analysis according to our Best Practices, your analysis will be greatly empowered by the ability to leverage population-wide information from a cohort of multiple samples. It will allow you to detect variants with great sensitivity and genotype samples as accurately as possible. See the following sections for details of why that is if you are not convinced.
Once you’re convinced: the good news is you don’t actually have to call variants on all your samples together. Since GATK 3.0, you can use the HaplotypeCaller to call variants individually per-sample in
-ERC GVCF mode, followed by a joint genotyping step on all samples in the cohort, as described in this method article. This achieves what we call incremental joint discovery, providing you with all the benefits of classic joint calling (as described below) without the drawbacks.
Why "almost always"? Because some people have reported missing a small fraction of singletons (variants that are unique to individual samples) when using the new method. For most studies, this is an acceptable tradeoff, but if you are very specifically looking for singletons, you may need to do some careful evaluation before committing to this method.
Until recently, three strategies were available for variant discovery in multiple samples:
- single sample calling: sample BAMs are analyzed individually, and individual call sets are combined in a downstream processing step;
- batch calling: sample BAMs are analyzed in separate batches, and batch call sets are merged in a downstream processing step;
- joint calling: variants are called simultaneously across all sample BAMs, generating a single call set for the entire cohort.
The best of these, from the point of view of variant discovery, was joint calling, because it provided the following benefits:
Batch-calling does not output a genotype call at sites where no member in the batch has evidence for a variant; it is thus impossible to distinguish such sites from locations missing data. In contrast, joint calling emits genotype calls at every site where any individual in the call set has evidence for variation.
By sharing information across all samples, joint calling makes it possible to “rescue” genotype calls at sites where a carrier has low coverage but other samples within the call set have a confident variant at that location. However this does not apply to singletons, which are unique to a single sample. To minimize the chance of missing singletons, we increase the cohort size -- so that singletons themselves have less chance of happening in the first place.
The current approaches to variant filtering (such as VQSR) use statistical models that work better with large amounts of data. Of the three calling strategies above, only joint calling provides enough data for accurate error modeling and ensures that filtering is applied uniformly across all samples.
Figure 1: Power of joint calling in finding mutations at low coverage sites. The variant allele is present in only two of the N samples, in both cases with such low coverage that the variant is not callable when processed separately. Joint calling allows evidence to be accumulated over all samples and renders the variant callable. (right) Importance of joint calling to square off the genotype matrix, using an example of two disease-relevant variants. Neither sample will have records in a variants-only output file, for different reasons: the first sample is homozygous reference while the second sample has no data. However, merging the results from single sample calling will incorrectly treat both of these samples identically as being non-informative.
There are two major problems with the joint calling strategy.
- Scaling & infrastructure
Joint calling scales very badly -- the calculations involved in variant calling (especially by methods like the HaplotypeCaller’s) become exponentially more computationally costly as you add samples to the cohort. If you don't have a lot of compute available, you run into limitations pretty quickly. Even here at Broad where we have fairly ridiculous amounts of compute available, we can't brute-force our way through the numbers for the larger cohort sizes that we're called on to handle.
- The N+1 problem
When you’re getting a large-ish number of samples sequenced (especially clinical samples), you typically get them in small batches over an extended period of time, and you analyze each batch as it comes in (whether it’s because the analysis is time-sensitive or your PI is breathing down your back). But that’s not joint calling, that’s batch calling, and it doesn’t give you the same significant gains that joint calling can give you. Unfortunately the joint calling approach doesn’t allow for incremental analysis -- every time you get even one new sample sequence, you have to re-call all samples from scratch.
This document describes the new approach to joint variant discovery that is available in GATK versions 3.0 and above.
This is meant to replace the joint discovery workflow that we previously recommended, which involved calling variants jointly on multiple samples, with a much smarter approach that reduces computational burden and solves the "N+1 problem".
This is the workflow recommended in our Best Practices for performing variant discovery analysis on cohorts of samples.
In a nutshell, we now call variants individually on each sample using the HaplotypeCaller in
-ERC GVCF mode, leveraging the previously introduced reference model to produce a comprehensive record of genotype likelihoods and annotations for each site in the genome (or exome), in the form of a gVCF file (genomic VCF).
In a second step, we then perform a joint genotyping analysis of the gVCFs produced for all samples in a cohort.
This allows us to achieve the same results as joint calling in terms of accurate genotyping results, without the computational nightmare of exponential runtimes, and with the added flexibility of being able to re-run the population-level genotyping analysis at any time as the available cohort grows.
Run the HaplotypeCaller on each sample's BAM file(s) (if a sample's data is spread over more than one BAM, then pass them all in together) to create single-sample gVCFs, with the following options:
--emitRefConfidence GVCF --variant_index_type LINEAR --variant_index_parameter 128000
If you have more than a few hundred samples, run CombineGVCFs on batches of ~200 gVCFs to hierarchically merge them into a single gVCF. This will make the next step more tractable.
Take the outputs from step 2 (or step 1 if dealing with fewer samples) and run GenotypeGVCFs on all of them together to create the raw SNP and indel VCFs that are usually emitted by the callers.
Finally, resume the classic GATK Best Practices workflow by running VQSR on these "regular" VCFs according to our usual recommendations.
That's it! Fairly simple in practice, but we predict this is going to have a huge impact in how people perform variant discovery in large cohorts. We certainly hope it helps people deal with the challenges posed by ever-growing datasets.
As always, we look forward to comments and observations from the research community!
Okay, we realize the name's a bit of a mouthful, and we're willing to tweak it if anyone has any good ideas. But never mind that. It's difficult to overstate the importance of this new approach to joint variant discovery (but I'll give it a shot) so we're really stoked to finally be able to share the details of how it's is going to work in practice.
You're probably going to be surprised at how simple it is in practice (not that it was particularly easy to actually build, mind you). The gory details are in the new document here, but here's an overview of how it looks within the Best Practices workflow you all know and (hopefully) love:
The first surprise is that instead of calling variants on multiple samples, you now just run HaplotypeCaller on each sample individually. "Oh no," I hear you cry, "but the results were so much better when I called multiple samples together!". Well yeah, but it took forever. Bear with me for a minute.
The key here is that you run HaplotypeCaller in gVCF mode. This outputs a so-called genomic VCF, which contains a record of the genotype likelihoods and annotations for every single site in the genome (or exome), whether or not there is evidence of variation. This essentially boils down all the useful information that can be gleaned from the BAM files, and makes it unnecessary to refer back to the BAM in later steps.
So you repeat that for all your samples (which goes reasonably fast since per-sample calling is pretty tractable nowadays). Optionally, you can add in a step to combine gVCF files if you're working on a really large cohort. Then in the next step, you just run a separate genotyping tool on all the gVCFs (or combined gVCFs) together, which gives you the same output (raw SNPs and indel calls) that you would have got from one-step multisample calling.
See, that's the beauty of the new workflow. A lot less work (for the computer) for equivalent results. And the ability to process samples incrementally and perform joint discovery on cohort sizes that would have previously got you hauled off to the funny farm.
Let us know what you think!
Yep, you read that right, the next release of GATK is going to be the big Three-Oh!
You may have noticed that the 2.8 release was really slim. We explained in the release notes, perhaps a tad defensively, that it was because we’d been working on some ambitious new features that just weren’t ready for prime time. And that was true. Now we’ve got a couple of shiny new toys to show for it that we think you’re really going to like.
But GATK 3.0 is not really about the new features (otherwise we’d just call it 2.9). It’s about a shift in the way we approach the problems that we want to solve -- and to some extent, a shift in the scope of problems we choose to tackle.
We’ll explain what this entails in much more detail in a series of blog posts over the next few days, but let me reassure you right now on one very important point: there is nothing in the upcoming release that will disrupt your existing workflows. What it will do is offer you new paths for discovery that we believe will empower research on a scale that has previously not been possible.
And lest you think this is all just vaporware, here’s a sample of what we have in hand right now: variant calling on RNA-Seq, and a multisample variant discovery workflow liberated from the shackles of time and scaling issues.
Stay tuned for details!